关键信息
-
基因名
MSP-1
- 应用
-
别名
MSP-1；VAP33；Vesicle-associated membrane Protein-associated Protein A
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P04932
-
表达区间
937-1260aa
-
氨基酸序列
KSSENFYEKILKDSDTFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFDKKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEKKKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQSQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVVTGEAVTPSV
-
分子量
40.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MSP-1 (Merozoite Surface Protein-1) is a critical immunogenic component of the malaria parasite Plasmodium falciparum, which is responsible for the most severe form of malaria. This protein plays a pivotal role in the lifecycle of the parasite, specifically during the invasion of host red blood cells by merozoites— the infectious stage of the parasite. Research on MSP-1 has gained significant attention due to its potential as a candidate for vaccine development aimed at controlling malaria. The protein's ability to elicit strong immune responses makes it a prime target for both vaccine formulation and diagnostic assay development. However, challenges remain in understanding the protein's structure-function relationship and its role in immune evasion. Scientists are exploring various recombinant techniques to produce MSP-1 in sufficient quantities and with appropriate configurations for effective use in clinical trials. Additionally, studies are focusing on identifying the specific immune responses generated against MSP-1 and their correlation with protection against malaria. Advancements in recombinant protein technology, coupled with novel adjuvant strategies, are expected to enhance the efficacy of MSP-1 based vaccines. The ongoing research on MSP-1 contributes to the broader goal of finding effective malaria interventions and could play a significant role in reducing the global burden of this devastating disease.
